Skip to content

Safety evaluation study on overdose of acacia bark extract (Acacia Polyphenol) in humans

Safety evaluation study on overdose of acacia bark extract (Acacia Polyphenol) in humans - Safety evaluation study on overdose of acacia bark extract (Acacia Polyphenol) in humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026288
Enrollment
30
Registered
2017-02-24
Start date
2017-02-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult

Interventions

4-week continuous intake of acacia bark extract 4-week continuous intake of placebo

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) 20<=Age=<64 of healthy men and women

Exclusion criteria

Exclusion criteria: (1) Subjects with diabetes, liver disease, kidney disease, gastrointestinal disease, peripheral vascular disease, or medical history for severe diseases (2) Subjects who indicate disorder of heart and lung function (3) Subjects who indicate abnormal parameter in liver or kidney function (4) Subjects who had a gastrointestinal surgery (5) Subjects with a disease under treatment now (6) Subjects with drug or food allergy (7) Subjects who play high intensity sports or are on a diet (8) Subjects who are taking medication or functional foods which might affect the results of this study, such as medicine, quasi drug and health foods (9) Subject who consume exscessive alcohol (10) Smoker (11) Subject who has been pregnant or subject who have a plan to become pregnant or breast feed during the study period (12) Subjects who is participating in the other study or plannning to participate during the study period (13) Subjects who isdeemed unsuitable by the principal investigator

Design outcomes

Primary

MeasureTime frame
Inquiry, physical examination, and medical examination by hematology, blood biochemistry, urinalysis

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness support Co., Ltd. Clinical trial Division

mterashima@oneness-sup.co.jp06-4801-8917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026